Transcription of the human papillomavirus type 18 (HPV18) E6 and E7 oncogenes is repressed by the viral E2 protein. In C33 cells, we have previously shown that of the four E2 binding sites (E2 BS) present in the HPV18 long control region (LCR), only the binding site adjacent to the TATA box (E2 BS 1) was involved in E2-mediated repression. In the present study, we sought to determine whether this phenomenon was conserved in other cell lines. We first showed that all three E2 BS proximal to the P 105 promoter were required for full repression of its activity in HeLa and HaCaT cells. Repression by E2 at E2 BS 2 occurred through the displacement of Sp1. Second, a truncated E2 product, lacking the N-terminal transactivation domain, repressed transcription more efficiently than the full-length protein. Repression was abolished when the Nterminal domain of E2 was replaced by the activation domain of VP16. The VP16-E2 chimeric protein could activate transcription from an LCR mutated in its TATA box. DNA-protein binding studies showed that E2 associates with its four binding sites in the LCR with similar affinities. However, challenge of such complexes with excess binding sites demonstrated that interaction with E2 BS 4 was the most stable while interaction with E2 BS 1 was the least stable. Furthermore, complexes with the full-length E2 were less stable than those formed with the N-terminally truncated protein.
A subgroup of the human papillomaviruses (HPVs) infects the epithelium of the genital tract. Some of them, such as HPV18, HPV16, and HPV33, are defined as high-risk viruses because of their association with lesions that may progress to cervical carcinoma. This oncogenic progression requires the continuous expression of the E6 and E7 viral oncogenes, whose products neutralize the action of the cellular tumor suppressor gene products p53 and pRb, respectively (12, 26, 30) . Transcription of the viral oncogenes is initiated at a single promoter, termed P 105 for HPV18 (36) , located at the 3Ј end of the long control region (LCR) of the viral genome. It is regulated by a complex array of cellular transcription factors (13) .
We have previously reported that transcription at the P 105 promoter is repressed by the viral E2 proteins (6, 9, 28, 37) . E2 binds as a dimer to the cognate DNA sequence ACCG(N 4 )C GGT (E2 binding site [E2 BS]) present in four copies at conserved relative positions in the LCRs of genital HPVs (10, 25) . Three of these sites, E2 BS 1 to 3, are confined to the proximal region of the promoter. E2 BS 1 lies only 3 nucleotides (nt) upstream of the P 105 TATA box, and E2 BS 2 lies only 1 nt downstream of an Sp1 binding site. Binding of Sp1 and the TATA box binding protein (TBP) to these sites is essential for promoter activity (8, 14, 20, 28, 37) . A fourth site, E2 BS 4, is located far from the other ones, upstream of the transcriptional enhancer.
E2-mediated transcriptional repression may play a role in the fate of HPV-infected lesions. In most of the HPV18-associated cervical cancers, the viral DNA is integrated into the cellular genome. The integration interrupts the E1 and E2 open reading frames (ORFs) (3, 31) . The encoded proteins are consequently not produced anymore, while the viral oncogenes are constitutively expressed from the natural viral promoter, which is no longer negatively regulated by E2. Therefore, disruption of the E2 gene may contribute to the neoplastic progression of HPV-associated lesions. Conversely, when E2 is exogenously expressed in HPV-associated cervical carcinoma cell lines, it represses transcription of the endogenous viral oncogenes, inducing growth arrest (11, 21) and apoptosis (7) .
In vitro studies have allowed scientists to postulate a mechanism for E2-mediated repression of the E6-E7 promoter. Binding of E2 to the two promoter-proximal E2 recognition elements (E2 BS 1 and 2) displaces TBP and Sp1 from their binding sites (6, 8, 9, 35) . Surprisingly, we had previously found that in the HPV-negative cervical carcinoma cell line C33, repression of P 105 requires only binding of E2 to E2 BS 1, the site most proximal to the TATA box (6, 37) . It appears that although the binding of E2 to E2 BS 2 in these cells displaces Sp1, it does not repress transcription. We have proposed that the occupancy of E2 BS 2 by E2 functionally replaces Sp1 (6) .
The E2 protein is a dimer whose modular structure is well conserved among papillomaviruses (10, 25) . Its N-terminal part contains a transactivation domain also involved in the initiation of viral DNA replication. The central domain, called the hinge, varies in length, and its structure is nonconserved. The C-terminal domain consists of about 100 amino acids that form a ␤-barrel structure responsible for the dimerization. It also binds specifically to DNA through two short ␣-helices that interact with the major groove of DNA (18) .
The aim of the present study was to investigate further the molecular basis of the E2-mediated transcriptional repression in different human epithelial cell lines. We found that P 105 repression was mediated by the binding of E2 to one or multiple sites within the LCR, depending on the cell type. Binding of E2 to E2 BS 1, the binding site most proximal to the TATA box, repressed transcription in HeLa, HaCaT, and C33 cells. However, in HeLa and HaCaT cells, E2 binding to E2 BS 2 and 3 also contributed to maximal transcriptional repression. In HeLa cells, E2-mediated repression through E2 BS 2 resulted from the displacement of Sp1 from its overlapping site. The N-terminal transactivation domain of E2 decreased transcriptional repression by destabilizing E2-DNA complexes. If the E2 transactivation domain was replaced by that of VP16, the chimeric protein prevented repression by recruiting the transcription initiation complex in a TATA-box-independent manner. We also showed that E2 bound with similar affinity to the four E2 BS of the HPV18 LCR, although the stabilities of the four different E2-DNA complexes differed greatly.
MATERIALS AND METHODS

Construction of plasmids. (i) CAT reporter plasmids.
HPV18 LCR-chloramphenicol acetyltransferase (CAT) reporter plasmids containing either the complete wild-type HPV18 LCR or this LCR mutated either in one or more of the E2 binding sites proximal to the P 105 promoter or by replacement of the P 105 TATA box by a GC-rich sequence were obtained by oligonucleotide reconstruction, as previously described (37) . CAT reporter plasmids containing the HPV18 LCR mutated in the sequences corresponding to E2 BS 2 and the Sp1 binding site were described previously (6) .
(ii) E2 expression plasmids. The HPV18 full-length E2 expression vector was constructed by cloning a fragment containing the whole HPV18 E2 ORF (from nt 2817 to 3917) with a reconstructed initiation codon in an NcoI site into the pCG vector downstream of the cytomegalovirus promoter. A fragment encompassing the E2 ORF from nt 3170 to 3917 was cloned in pCG to express the N-terminally truncated form of HPV18 E2, E2DBD. This fragment contains a natural in-frame ATG at position 3213, used as the translation initiation codon (37) . The expression plasmid for full-length bovine papillomavirus type 1 (BPV1) E2 has been previously described (38) , as has the VP16-E2 fusion protein (22) . The plasmid used for expression of His-tagged full-length HPV18 E2 in bacteria has been described elsewhere (6) . The expression vector for the His-tagged HPV18 E2 dimerization-DNA binding domain was constructed with a fragment encompassing the HPV18 E2 ORF from nt 3542 to 3917 cloned in phase downstream of a short sequence coding for six histidines in the pET14B plasmid (Novagen). The resulting proteins contain six histidines added in frame at their N termini. pE1TTL was used as a negative control; it contains downstream of the cytomegalovirus promoter the HPV18 E1 ORF with a translation termination linker (TTL) inserted at position 1128; this construct was actively transcribed but not translated.
Cell cultures and transient transfections. Cells were grown in Dulbecco's modified Eagle medium supplemented with 7% fetal calf serum. Transient transfections of C33 and HeLa cells were performed by the standard DNA-calcium phosphate coprecipitation method as described in reference 6, using 2 g of CAT reporter plasmid and either 1 g of pE1TTL as a negative control (7), 1 g of HPV18 E2 expression plasmid (HPV18 E2 or E2DBD), or 0.25 g of BPV1 E2-expressing vector. HaCaT cells were transfected with the DOTAP reagent (Boehringer Mannheim) according to the manufacturer's instructions, using 2 g of reporter plasmid and 3 g of HPV18 E2 expression plasmid. Some experiments were performed with 1 g of E2 expression plasmid, giving results identical to those presented here.
Production and purification of His-tagged HPV18 E2. His-tagged HPV18 E2 proteins, either full length or N-terminally truncated, were produced in Escherichia coli BL21 in accordance with the instructions of the manufacturer (Novagen) and were purified on a nickel column (19) .
DNA binding assays. Double-stranded oligonucleotides that were end labelled with [ 32 P]dATP by the Klenow fragment were used as probes. They contained the core sequences of the four E2 BS of the HPV18 LCR with flanking sequences as follows (the conserved palindromes recognized by E2 are underlined): BS 1, 5Ј-CGGGACCGAAAACGGTGTATATAAAAGATGTGAGAAACACAC-3Ј; BS 2 5Ј-AATTGTAGTATATAAAAAAGTTAGTGACCGAAAACGGTCGG G-3Ј; BS 3, 5Ј-CTAGATGCAACCGAAATAGGTTGGGCTCTAG-3Ј; and BS 4, 5Ј-CTAGTGCAACCGATTTCGGTTGCCTTTGGCTTATGTCTAG-3Ј. Binding reactions were carried out in a final volume of 20 l in a solution containing 12 mM HEPES (pH 7.9), 10% glycerol, 0.5 mM EDTA, 4 mM MgCl 2 , 60 mM KCl, 8 mM dithiothreitol, 1 g of dI-dC, and 5 g of bovine serum albumin. Reaction mixtures were preincubated for 15 min at 4°C, and after addition of 32 P-end-labelled probes, they were further incubated for 5 min at room temperature. When necessary, specific competitor oligonucleotides were added to the reaction mixtures along with the labelled probe. The samples were loaded onto a 6% polyacrylamide gel in 0.25ϫ Tris-borate-EDTA and electrophoresed in 0.5ϫ Tris-borate-EDTA at 180 V for 2 h. After fixation, the gels were dried and autoradiographed. The radioactive signals were quantified with a phosphorimager, and the ratio of free DNA to bound DNA was calculated. Saturation binding experiments were performed by incubating serial dilutions of a preparation of the His-tagged purified HPV18 E2 dimerization-DNA binding domain with a constant amount of labelled probe. From experiments done in parallel with the four probes, bound DNA was quantified for each protein dilution. Fractions of bound DNA were plotted relative to the values of bound DNA at the saturation plateau, set at 100% of binding for each probe. The advantage of this method is that measurements are independent of the concentration and specific activities of the labelled oligonucleotides, allowing a comparative measure of the affinity of E2 for each of its binding sites.
Dissociation rates were measured under the conditions described above. Double-stranded probes were either those described above or others that contained E2 BS 4 or 1 with either only two or four of the natural flanking nucleotides and with overhanging XbaI sites for labelling. Each labelled oligonucleotide was incubated with an adequate dilution of each of the purified E2 proteins, and the reactions were allowed to reach equilibrium by incubation for 5 min at room temperature. At time zero, 20 l of the reaction mixture was removed, and then a 1,000-fold excess of a specific nonradioactive competitor oligonucleotide containing either E2 BS 4 or E2 BS 1, depending on the experiment, was added. Equivalent volumes were removed at various time intervals and loaded on a 6% polyacrylamide running gel.
RESULTS
Distinct E2 binding sites are involved in P 105 repression depending on the cell types. We checked for the involvement of the three P 105 -proximal E2 binding sites (E2 BS 1 to 3) in the transcriptional repression of HPV18 viral oncogenes by HPV18 E2 in three different human epithelial cell lines. We used two cell lines established from cervical carcinomas, either HPV associated (HeLa) or HPV negative (C33), and one line of spontaneously immortalized human keratinocytes (HaCaT). Transcription was monitored by measuring the CAT activity of CAT reporter plasmids containing either the wild-type HPV18 LCR or the LCR mutated in one or more of the E2 BS (Fig.  1) , cotransfected with the expression vector for the HPV18 E2 protein.
In C33 cells, the basal level of HPV18 P 105 activity was decreased twofold upon expression of HPV18 E2 (Fig. 2) . Mutation of E2 BS 1 completely relieved this repression, confirming that binding of E2 to this site was the major cause of transcriptional repression, as previously shown (6, 37) . The situation was different in HeLa and HaCaT cells in which the three E2 BS participated to the repression, which was stronger than in C33 (25-and 20-fold for HeLa and HaCaT cells, respectively). When E2 BS 1 was mutated, transcription at the P 105 promoter was still repressed by HPV18 E2 (about fivefold). When both E2 BS 1 and 2 were mutated, transcription repression decreased to roughly twofold. Mutation of all three promoter-proximal E2 BS fully relieved E2-mediated repression of P 105 transcription and led to a three-to sixfold activation of transcription. This activation probably depends on the binding of E2 to E2 BS 4 as recently suggested (32) . We thus confirmed that E2-mediated repression was dependent only on the integrity of E2 BS 1 in C33 cells while it required two additional binding sites (E2 BS 2 and 3) in HeLa and HaCaT cells.
Displacement of Sp1 by E2 contributes to the repression of P 105 in HeLa cells. We have previously shown that the binding of HPV18 or BPV1 E2 to E2 BS 2 in vitro displaces Sp1 bound to its overlapping site (6) . Considering that the integrity of the Sp1 site is essential for P 105 activity in C33 and HeLa cells (references 5 and 20 and data not shown) and that E2 BS 2 also participates in repression in HeLa and HaCaT cells, we examined whether displacement of Sp1 by HPV18 E2 in HeLa cells accounted for the repression of P 105 mediated by E2 bound to E2 BS 2.
We used a mutated promoter containing an insertion of 7 nt between the Sp1 binding site and E2 BS 2. This modification allows concomitant binding of both Sp1 and HPV18 E2 proteins in vitro (6) . CAT activity from this plasmid was repressed by E2 at levels comparable to a wild-type LCR-CAT vector (Fig. 3) . This repression could be caused by binding of E2 to E2 BS 1, which could mask the importance of upstream E2 BS. Therefore, we examined the role of Sp1 displacement with promoter sequences mutated in E2 BS 1. In this context, E2 expression still repressed the mutated promoter about fivefold, while moving the Sp1 binding site away from E2 BS 2 resulted in an almost complete loss of repression by E2 (1.3-fold) . These results indicated that repression mediated by binding of HPV18 E2 to E2 BS 2 was due to displacement of Sp1.
The N-terminal domain of E2 influences the level of P 105 repression. Despite the contributions of all three E2 BS to the E2-mediated repression of P 105 in HeLa and HaCaT cells, E2 BS 1 remains an important site for repression. In C33 cells, it is the only site involved. It has been shown that binding of BPV1 E2 to E2 BS 1 negatively interferes with the formation of the transcription initiation complex. This repression, due to the proximity of E2 BS 1 and the TATA box, involves competitive binding of E2 and TBP to their recognition elements (9) . N-terminally truncated forms of BPV1 or HPV18 E2 mediate repression of P 105 transcription, since they fully retain specific DNA binding. However, we decided to examine whether the N-terminal domain could influence the level of E2-mediated repression since it carries the potential to interact with transcription factors and to modify the structure of the chromatin.
We analyzed the level of P 105 transcription in the presence of different forms of HPV18 and BPV1 E2 in C33 cells (Fig.  4A ). Various levels of P 105 repression were observed with the different proteins, although expression levels and binding efficiencies were comparable ( Fig. 4C ; see also initiation complex. To test this hypothesis, we used a hybrid protein in which the strong VP16 transactivation domain replaced that of BPV1 E2. The VP16-E2 fusion protein bound to E2 BS and activated E2-inducible plasmids up to 100-fold (data not shown). However, it failed to repress P 105 transcription in C33 or HeLa cells (data not shown), in contrast to the full-length BPV1 E2, which greatly repressed transcription in both cell lines (Fig. 4B and data not shown) . The VP16 transactivation domain has been shown to interact with crucial elements of the transcription initiation complex. Therefore, it might recruit the transcription initiation complex, even though binding of VP16-E2 to E2 BS 1 sterically hinders the access of TBP to the TATA box. To validate this hypothesis, we used a P 105 promoter mutated in the TATA box (Fig. 5) . This mutation strongly decreased the basal level of transcription (200-fold in HeLa cells and 25-fold in C33 cells), which was further repressed by HPV18 and BPV1 E2. In contrast, this mutant promoter was activated by the VP16-E2 fusion protein in both cell lines, although the final activity remained lower than that of the intact P 105 promoter. These results indicated that the transactivation domain of VP16 could recruit a transcription initiation complex to a TATA-less promoter, counteracting the repression due to the interference with TBP binding to the TATA box. In contrast, neither the BPV1 nor the HPV18 full-length E2 protein was able to activate a TATA-less promoter, suggesting that E2 is unable to recruit the general transcription factors necessary for the initiation of transcription in this specific configuration.
E2 binds to the four E2 BS of the HPV18 LCR with similar affinities but different stabilities. The results described above imply that E2 binds with high affinity to the two proximal sites involved in transcriptional repression (E2 BS 1 and 2), since repression involves the displacement of cellular transcription factors from their overlapping sites. Since the roles of E2 BS 3 and 4 in repression were minor and nonexistent, respectively, they might bind E2 with lower affinity. Therefore, we studied the relative binding characteristics of the four E2 BS in vitro.
We performed titration curves with serial dilutions of the purified truncated HPV18 His-tagged E2 protein and a constant amount of each of the four probes (Fig. 6A) . In vitrotranslated His-tagged and native E2 proteins bind DNA with similar affinities (data not shown). The active fraction of the E2 protein was not known, precluding any calculation of the absolute equilibrium constant (K eq ). By comparing the protein dilution at 50% binding of labelled probe in assays performed in parallel with the four probes, we deduced that the affinities of the DNA binding domain of E2 for the four sites differed by less than twofold (Fig. 6B) . We confirmed by competition experiments that E2 bound to each E2 BS within a close range of affinity values. E2 bound the three proximal sites with similar affinities, two-to fourfold lower than that for E2 BS 4 (data not shown).
We then examined the dissociation rates of the four E2-DNA complexes, since it has previously been shown that this kinetic parameter differs greatly from one site to an other in BPV1 (23) and in HPV16 (29) . The dissociation rates of the protein-DNA complexes were measured following the addition of a 1,000-fold excess of specific unlabelled competitor to reactions that had already reached equilibrium. As shown in Fig.  7 , the E2-E2 BS 1 complex was ϳ10-, 4-, and 30-fold less stable than E2-E2 BS 2, E2-E2 BS 3, and E2-E2 BS 4, respectively. We next attempted to determine whether the E2 N-terminal transactivation domain could influence the stability of E2 binding. Complexes containing the His-tagged full-length E2 protein bound to DNA were approximately threefold less stable than those containing the truncated E2, although the relative range of dissociation values for the four sites was conserved (Fig. 7) . We failed to observe a correlation between the apparent equilibrium values and the stabilities of the complexes in the presence of excess binding sites. Oligonucleotides containing the palindrome and the two flanking nucleotides from E2 BS 4 retained a high degree of stability in contrast to oligonucleotides containing the two adjacent nucleotides of E2 BS 1 (data not shown). Therefore, the two nucleotides flanking the conserved palindrome appear to be responsible for the differences in stability. Their importance may come from the fact that they are also involved in protein-DNA contacts, as revealed by X-ray resolution of the structure (18).
DISCUSSION
We have previously shown that P 105 transcription is repressed by the viral regulator E2. We showed in this study that multiple events are involved in this process, the contributions of which differ depending on the cell type. The downstreammost E2 binding site abuts the P 105 TATA box. Binding of E2 to this site has been shown to sterically hinder the formation of the transcription initiation complex (9) . The importance of this mechanism is illustrated by the fact that binding of E2 to this site caused repression in all three cell lines tested. On the other hand, binding of E2 to the upstream E2 BS 2 displaces Sp1 from its binding site (6, 8, 35) . However, this displacement does not cause repression in C33 cells (6) . In contrast, in HeLa cells, binding of E2 to E2 BS 2 repressed transcription by displacing Sp1, since moving the Sp1 binding site away from E2 BS 2 abolished this repression. This indicates that in HeLa cells, E2 could not activate P 105 by replacing Sp1, as has been proposed for C33 cells. We have previously hypothesized that in C33 cells, Sp1 modifies the chromatin structure of the promoter sequences, a role that could be taken over by E2 in the absence of Sp1 (6) . In HeLa cells, Sp1 could, in addition to modifying the chromatin structure, stabilize the transcription initiation complex through specific interactions that E2 cannot perform. One should also recall that Sp1 belongs to a family of transcription factors that bind identical GC-rich boxes. Among them, Sp3 is unable to activate transcription and is a negative competitor of Sp1 (17) . Since Sp1/Sp3 ratios have been shown to influence the activity of the HPV16 E6/E7 promoter (1), it is possible that the Sp1/Sp3 ratios in C33 and HeLa cells are different.
In HeLa and HaCaT cells, binding of E2 to E2 BS 3 also participated in repression of P 105 transcription. At the moment we can only speculate that binding of E2 to this site might hinder the binding of a potent transactivator of P 105 transcription. In footprinting experiments, we have previously shown that an abundant cellular factor could protect a region overlapping E2 BS 3 (13) . This region, named footprint VIII, has not yet been characterized, although its cognate DNA sequence resembles an OCT1 binding site. Alternatively, since E2 BS 3 is located between the enhancer and the promoter region, binding of E2 to this site might interfere with the communication between the enhancer and the promoter elements, as has previously been suggested (16) . However, multiple interfering mechanisms contribute to the transcriptional repression of P 105 mediated by E2, a situation which has also been described for HPV16 and HPV11 (8, 35) . When the three E2 BS proximal to the promoter were mutated, we found that HPV18 E2 could activate transcription four-to fivefold. This activation may result from the binding of E2 to the upstreammost E2 BS 4. Therefore, E2-mediated regulation of P 105 activity might reflect a balance between repression, through the three proximal sites, and activation, through the upstreammost site.
A chimeric protein containing the VP16 transactivation domain fused to the DNA binding-dimerization domain of BPV1 E2 (22) did not repress P 105 but activated its transcription when the TATA box was mutated. These results suggest that VP16 might recruit the transcription initiation complex even in the absence of a TATA box, thereby compensating for the displacement of TBP from the genuine TATA box. This hypothesis is strengthened by the finding that the acidic transactivation domain of VP16 interacts with TBP, TFIIB, TFIIH, and TBP-associated factors (TAFs) (15, 24, 34, 39) . In contrast, full-length E2 might not be able to directly recruit the transcription initiation complex, since neither HPV18 E2 nor BPV1 E2 could activate transcription from the TATA-less promoter even though BPV1 E2 has been shown to interact with TBP and TFIIB through its hinge and C-terminal domains, respectively (27, 33) . Since the HPV18 full-length E2 protein repressed transcription less efficiently than a truncated protein lacking the entire transactivation domain, and since there was no evidence for recruitment of transcription factors by the E2 N-terminal transactivation domain, we examined the possibility that fulllength and truncated E2 might bind DNA with different kinetics. We found that E2-DNA complexes formed in vitro with the full-length HPV18 E2 were about threefold less stable than those formed with the truncated version of the protein. With the full-length protein, the complex formed with E2 BS 1 exhibited the shortest half-life (about 1 min) when challenged with excess binding sites. These differences might play an important role in vivo, particularly in C33 cells, in which binding of E2 to E2 BS 1 is essential for repression, and might explain the relatively low level of repression observed with full-length HPV18 E2 in these cells. E2 has been shown to be a potent suppressor of growth of cervical carcinoma cells (7, 11, 21) and to induce apoptosis in HeLa cells (7) . The E2 DNA binding domain alone did not efficiently induce these phenomena. Our finding that HPV18 E2DBD is a more potent repressor of P 105 transcription than the full-length protein supports the hypothesis that repression of endogenous transcription of the E6 and E7 oncogenes by E2 is not sufficient and that an additional mechanism involving the E2 transactivation domain is required for E2-mediated growth suppression and apoptosis.
The E2 binding sites of the HPV18 LCR are well conserved in their essential palindromic sequence ACCG(N 4 )CGGT, with the exception of E2 BS 3, which contains a single substitution (underlined) within the palindrome [ACCG(N 4 )AGGT]. In addition, the four sites contain AT-rich intervening sequences which have been shown to enhance the binding affinities of genital E2 proteins (2) . Given these characteristics, we predicted that E2 would bind to the four E2 BS with similar affinities, as previously shown for HPV16 (29) . We found that the four E2 BS of the HPV18 LCR have very similar relative affinities, as calculated from saturation or competition experiments. However, the rates of dissociation of the four different E2-DNA complexes differed markedly in the presence of a large excess of nonlabelled specific oligonucleotide, as previously shown for HPV16 (29) . In vitro, E2 BS 4 exhibited a 30-fold-slower dissociation rate than E2 BS 1. Interestingly, binding to E2 BS 2 was the second most stable interaction. Therefore, E2 BS 4 may be the first site occupied at low levels of E2, followed by E2 BS 2, E2 BS 3, and then E2 BS 1. Obviously this situation might be modulated in vivo by stabilizing interactions with cellular factors. Occupancy of E2 BS 4 by E2 may allow activation of P 105 transcription at low concentrations of E2, while an increase in the E2 concentration would result in repression, as proposed by others (4, 32) . However, we never observed transcriptional activation of P 105 in transient transfection experiments. We feel that such a hypothesis could be convincingly demonstrated only with inducible systems allowing fine tuning of E2 expression. On the other hand, occupancy of the three E2 BS proximal to the early promoter plays a fundamental role in the viral vegetative cycle, since it participates in the activation of viral DNA replication. Variations in stability of the E2 interaction with these sites might therefore modulate both replication and transcriptional repression during the viral vegetative cycle. FIG. 7 . Dissociation of E2-DNA complexes in the presence of an excess of nonradioactive specific oligonucleotide. Labelled oligonucleotides, at a final concentration of 2 ϫ 10 Ϫ10 M, were incubated with a fixed final concentration of 7 ϫ 10 Ϫ9 M E2DBD or 4 ϫ 10 Ϫ9 M full-length E2. After the reactions reached equilibrium (time point zero), a 1,000-fold excess of the unlabelled oligonucleotide containing E2 BS 4 was added. Aliquots were then taken at various time points and loaded on 6% polyacrylamide running gels. The core sequences of the four E2 BS are indicated under the graph; the palindromes are underlined. The two flanking nucleotides of each sequence, which are involved in the stability of the interaction, are shown in boldface. The half-lives of the complexes (t1/2) determined from these experiments are also given at the bottom.
